Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

Burkholz, S. R., Herst, C. V., Carback, R. T., Harris, P. E., & Rubsamen, R. M. (2023). Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study. Vaccines, 11(3), 644. https://doi.org/10.3390/vaccines11030644
Authors:
Scott R Burkholz
Charles V Herst
Richard T Carback
Paul E Harris
Reid M Rubsamen
Affiliated Authors:
Paul E Harris
Columbia Affiliation:
Author Keywords:
bioinformatics
birc5
breast cancer
immunotherapy
neoadjuvant therapy
next-generation sequencing
survivin
tumor-associated antigen
elink
Publication Type:
Article
Unique ID:
10.3390/vaccines11030644
PMID:
36992227
DOI:
10.3390/vaccines11030644
Journal:
Vaccines
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: